Moderna has decided to shift production to its own facilities in the US and elsewhere.
Gaetan Bally
Swiss pharmaceutical supplier Lonza will stop production of the Covid-19 vaccine for Moderna at its Visp site in the third quarter of 2023. Moderna will cover its demand for the vaccine from its own production facilities in the future, the US company announced on Tuesday.
This content was published on
1 minute
Keystone-SDA
US vaccine maker Moderna is focusing production of the mRNA agent at fewer sites as demand has declined with the transition from a pandemic to an endemic market, the statementExternal link added. Lonza could not initially be reached for comment by the Swiss business news agency AWP.
Moderna will meet vaccine demand for 2024 and 2025 from its own sites in Norwood, Massachusetts, it said. More capacity will be added starting in 2025 when Moderna’s new mRNA production facilities in the UK, Canada and Australia come online, according to the statement.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Climate change
Switzerland turns train tracks into solar power plants
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
Basel prepares 700 volunteers for the Eurovision Song Contest
This content was published on
Around 320 people took part in one of the two official information events for the Eurovision Song Contest (ESC) in Basel on Friday.
More Swiss soldiers involved in accidents during training in Austria
This content was published on
The Swiss army has reported various accidents involving Swiss soldiers during the exercise “TRIAS 25” in Austria. Some have led to hospitalisations.
Swiss court rules vegan meat substitutes can’t use animal names
This content was published on
Vegan meat substitutes may not bear animal names such as “planted.chicken” according to a ruling by the Swiss Federal Supreme Court.
Swiss cantons spared duty to create new traveller transit sites
This content was published on
Swiss cantons will no longer be formally obliged by the government to create new transit sites for the travelling community.
Swiss politicians bemoan limited access to EU treaty details
This content was published on
Protests that only a few Swiss parliamentarians will be able to read the contents of a new agreement negotiated with the EU.
This content was published on
For the first time, most Swiss residents favour withdrawing their pension pot as a lump-sum over regular annuity payments.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Explainer: should we be worried about the Covid-19 comeback?
This content was published on
Switzerland and the US have issued Covid-19 vaccination recommendations for this winter. Here is what we know so far about variants and vaccines.
Lonza to double production of Covid-19 vaccine at Swiss plant
This content was published on
The Swiss firm will add three more production lines to its plant as part of a larger effort to boost Moderna’s global supply of vaccine doses.
New Lonza site can now make Covid-19 vaccine ingredient
This content was published on
Swissmedic, the Swiss Agency for Therapeutic Products, has approved Lonza’s new site for making Moderna’s Covid-19 active substance.
Vaccines and beyond: How AI is shaping our pandemic response
This content was published on
The race to vaccinate against Covid-19 has science running at full speed, unravelling age-old mysteries with the help of artificial intelligence (AI).
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.